ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group Biomarker-driven research involving adults who have or are at risk of developing cancer

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adult...
03/13/2026

Clinical trial MM1OA-EA02, led by Dr. Jessica Altman of the Lurie Cancer Center, aims to improve results for older adults with acute myeloid leukemia (AML). Learn more: https://bit.ly/mm1oa-ea02-study

Do you have newly diagnosed glioblastoma? If so, you may be able to participate in this study of a new treatment approac...
03/13/2026

Do you have newly diagnosed glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial

: Checkpoint blockade continues to reshape treatment. E4412, recently published in , shows that adding ipilimumab to ...
03/13/2026

: Checkpoint blockade continues to reshape treatment. E4412, recently published in , shows that adding ipilimumab to BV + nivolumab did not significantly improve CR rates; safety profiles were similar. More: https://bit.ly/4s3BG14

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

In clinical trial EA2222/PUMP, investigators are testing pump chemotherapy in addition to standard-of-care (SOC) chemoth...
03/12/2026

In clinical trial EA2222/PUMP, investigators are testing pump chemotherapy in addition to standard-of-care (SOC) chemotherapy versus SOC chemotherapy alone for patients with unresectable colorectal cancer liver metastases. For more: https://bit.ly/ea2222-pump

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the ...
03/12/2026

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. https://bit.ly/ea8231-study

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck...
03/12/2026

Clinical study EA3191 is testing a new treatment approach for patients with squamous cell carcinoma of the head and neck (HNSCC) that has come back after initial therapy. Learn more: https://bit.ly/ea3191-study

New overview of systemic therapy advances in highlights several pivotal trials—including E2211 (led by Dr. Pamela Kunz...
03/12/2026

New overview of systemic therapy advances in highlights several pivotal trials—including E2211 (led by Dr. Pamela Kunz). These studies continue to shape treatment strategies and sequencing in this rare cancer. Read more:

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

In clinical trial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients w...
03/11/2026

In clinical trial EA7222, investigators are testing doxorubicin plus pembrolizumab vs. doxorubicin alone for patients with advanced undifferentiated pleomorphic sarcoma (UPS). For more information: https://bit.ly/EA7222

Do you have advanced has become worse following treatment, or advanced cancer for which no standard treatment exists? ...
03/11/2026

Do you have advanced has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the study. Learn more: http://bit.ly/ComboMATCH

Do you have an aggressive B-cell lymphoma that has either come back or persisted after initial therapy? If so, you may b...
03/10/2026

Do you have an aggressive B-cell lymphoma that has either come back or persisted after initial therapy? If so, you may be eligible to participate in clinical trial EA4231. More info here: https://bit.ly/EA4231

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy ...
03/10/2026

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trial

New data show research grant success rates plummeted in 2025—falling to around ~19–20% overall & hitting early-career ...
03/10/2026

New data show research grant success rates plummeted in 2025—falling to around ~19–20% overall & hitting early-career scientists especially hard. The ripple effects could shape the biomedical workforce for years. More: https://bit.ly/46PsJjq

Agency acknowledges young investigators are losing out as result of multiyear funding policy imposed by White House

Address

Philadelphia, PA

Telephone

+12157893631

Website

http://linktr.ee/ecog_acrin

Alerts

Be the first to know and let us send you an email when ECOG-ACRIN Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

We design and conduct cancer clinical trials, which are available to patients at nearly 1,200 member cancer centers and community hospitals in the US and internationally. We focus our research on adults who have or are at risk of developing cancer. The group is dedicated to achieving advances in all aspects of cancer care across all types of cancer. Our goal is to reduce the burden of cancer and improve the quality of life and survival in patients. Our primary source of funding is the National Cancer Institute, part of the National Institutes of Health.